CD34 and myeloid sarcoma: Functional inactivation of the α4 integrin has been observed following mobilization of CD34+ hematopoietic stem cells [25], and it is known that these cells are mobilized by natalizumab when it is used in the treatment of patients with MS [26]–[29].